PCI was introduced to Hong Kong a little later than the US and Europe. The first PTCA was done in Hong Kong in April 1985. Since then, there has been tremendous development in PCI technology and the techniques of PCI operators. Assisted devices have been widely used including directional atherectomy, rotational atherectomy, laser angioplasty, brachy therapy and stents. Drug-eluting stents have been the main stay of treatment for over 60%~70% of the PCI procedures. In recent years, we have witnessed the inadequacy of coronary angiography and much attention has been focused on other coronary imaging modalities including IVUS, virtual histology and OCT. Physiological assessment of coronary lesions with FFR is more frequently done nowadays. When we are dealing with a complex borderline lesion, we will assess with FFR, decide on plaque composition and stent size with IVUS-VH and ensure good stent apposition with OCT. There has been exponentially growth in the number and complexity of PCI procedures performed and in 2011, more than 10000 PCI procedures have been performed in HongKong.

         For continuous quality improvement and to maintain the standard of care of PCI procedures, the Hospital Authority has taken initiatives to conduct aterritory-wide PCI Audit in Hong Kong. According to the 2003-2006 dataset, the overall 72-hour mortality of PCI in Hong Kong was 0.6% and the combined major complication rate was 1.6% . We were able to build a Hong Kong PCI Risk Prediction Model in which the predictors of mortality included cardiogenic shock, unstable angina, intercurrent VT/VF, renal failure, history of CVA, left main involvement and primary/rescue PCI for STEMI and the predictors for non-death major complications were type B2/C lesions, cardiogenic shock, intercurrent VT/VF, history of CVA and age more than 70years old. With these, patients could be better informed of their PCI procedures.PCI Audit is a continual project toensure the standard and safety of PCI procedures done in the Hospital Authority.

       Other areas of cardiovascular intervention have also been developed at a fascinating pace including peripheral, congenital and structural heart interventions. The first Transcatheter Aortic Valve Implantation (TAVI) in the Greater China area was performed in Queen Elizabeth Hospital of Hong Kong on 6 Dec 2010. TAVI procedures have been performed to date in Queen Elizabeth Hospital with 0% 30-daymortality and 15.4% pacemaker rate. The number of TAVI procedures is expected to increase steadily in the years to come. We have also participated in the Asia TAVI Registry to monitor the outcomes of this new technology. The MitraClip procedure is also expected to start in the second quarter of 2012.

       Hong Kong Society of Transcatheter Endocardiovascular Therapeutics(HKSTENT), the first charitable interventional organization in HongKong, was established in November2010. Our mission is to provide educational activities for the cardiology community, enhance training of our fellows, nurses and paramedics, and organize research opportunities inc ardiovascular interventions. Over thepast year or so, we have organized anumber of workshops and symposia such as the Coronary Physiology and Imaging Symposium, CTO Case Sharing Workshop, Rotablator Workshop and case sharing session with Korean ardiologists in Seoul. The HKSTENT Left Main PCI Registry has been presented in our Inauguration Symposium in 2010. On 3~4 March2012, we have successfully organized the HKSTENT Cardiovascular Intervention Complication Forum (CICF)2012. Faculties and fellows shared their most challenging complication cases and we all learned through their tips and ricks. This year, we have partnered with CIT 2012 to co-organize the HKSTENT@CIT session on 15 Mar. Distinguished faculties will share their experience in Cardiac Imaging and Physiology while selected complication cases will be shown to arouse interest in learning through interventional scenarios.

      The future of cardiovascular intervention in Hong Kong can only be more exciting and fascinating. While balancing between new technology and safety of new devices, we will definitely keep pace with the latest development for the ultimate benefit of our patients.